InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Requadt Scott, Chairman & CEO. Officer active across 2 companies, notably Talaris Therapeutics, Inc.. In total, 9 disclosures have been logged. Breakdown: 3 buys · 0 sell. Total volume traded: €222k. History available since 31 December 2021. The latest transaction was disclosed on 30 October 2023 (J). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Requadt Scott
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations9 total
30,002 sharesCommon SharesSEC:0001104659-25-099650:0
17,502 shares0Common SharesSEC:0001209191-24-001597:0
11,786 shares@ US$3.0811.5% of flowCommon StockSEC:0001209191-23-041610:0
4 shares@ US$0.8670.0% of flowCommon StockSEC:0001209191-23-006998:0
80,000 shares0Common StockSEC:0000899243-22-030931:0
39,382 shares@ US$4.2556.8% of flowCommon StockSEC:0000899243-22-027404:0
Canonical exit: 27 Oct 2022 (T+90)
5,528 shares@ US$4.248.0% of flowCommon StockSEC:0000899243-22-026986:0
Canonical exit: 24 Oct 2022 (T+90)
9,444 shares@ US$3.749712.0% of flowCommon StockSEC:0000899243-22-026759:0
Canonical exit: 20 Oct 2022 (T+90)
1,470 shares@ US$13.0050.0% of flowCommon StockSEC:0000899243-22-004202:0
9 of 9 declarations
About Requadt Scott
Scott Requadt is the Chief Executive Officer of Talaris Therapeutics, Inc. He oversees the company's operations and is responsible for the overall strategy. His experience in the biopharmaceutical sector enables him to effectively lead Talaris towards innovation and growth.
